Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Destiny Pharma. Share Price
  4. Destiny Pharma. Share Regulatory News
  5. Presenting at HC Wainwright Investment Conference

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Destiny Pharma. Information

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.00
Bid: 10.50
Ask: 11.50
Change: 0.50 (4.76%)
Spread: 1.00 (9.524%)
Open: 10.50
High: 11.00
Low: 10.50
Prev. Close: 10.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Presenting at HC Wainwright Investment Conference

7 Sep 2022 07:03

RNS Number : 5119Y
Destiny Pharma PLC
07 September 2022
 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma CEO, Neil Clark, to present

at the HC Wainwright 24th Annual Global Investment Conference

 

Brighton, United Kingdom - 7 September 2022 - Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces that Destiny Pharma's CEO, Neil Clark, will present virtually at the upcoming HC Wainwright 24th Annual Global Investment Conference, being held on 12-14 September 2022 in New York and virtually.

The presentation will be available to view on demand from 1200 BST / 0700 ET on Monday 12 September 2022. To join the conference virtually, view the presentation and ask any questions, please click on the link above to register.

Presentation Title: Destiny Pharma Company Presentation

Presenter: Neil Clark

If you would like to meet with Destiny Pharma, please email us at conferences@destinypharma.com or contact us through the HC Wainwright conference meeting system if you are registered.

For further information, please contact:

Destiny Pharma plc Neil Clark, CEOShaun Claydon, CFO+44 (0)1273 704 440 pressoffice@destinypharma.com

Optimum Strategic Communications Mary Clark / Manel Mateus +44 (0) 208 078 4357 DestinyPharma@optimumcomms.com

MC Services AGAnne Hennecke / Andreas Burckhardt+49-211-529252-12

Stern IR - US

Lilian Stern / Janhavi Mohite

+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAMZGGLRVVGZZM
12345
Date   Source Headline
6th Jan 20218:00 amRNSDestiny Pharma Appoints Stephanie Bewick as CBO
5th Jan 20217:00 amRNSPhase 2b trial of XF-73 completes recruitment
23rd Dec 20202:09 pmRNSGrant of share options
22nd Dec 20207:00 amRNSUpdate on the recently acquired NTCD-M3 programme
1st Dec 20205:23 pmRNSHolding(s) in Company
30th Nov 20202:00 pmRNSHolding(s) in Company
26th Nov 202010:50 amRNSResult of General Meeting and Total Voting Rights
25th Nov 20207:00 amRNSResult of Open Offer
9th Nov 20204:25 pmRNSFundraising and Acquisition
12th Oct 20207:00 amRNSClinical Study Patient Recruitment Update
17th Sep 20207:00 amRNSInterim results for the 6 months ended 30 Jun 2020
17th Sep 20207:00 amRNSUpdate on Phase 2b clinical study of XF-73
10th Sep 20207:00 amRNSNotice of Results
7th Sep 20204:40 pmRNSSecond Price Monitoring Extn
7th Sep 20204:35 pmRNSPrice Monitoring Extension
7th Sep 20202:06 pmRNSSecond Price Monitoring Extn
7th Sep 20202:01 pmRNSPrice Monitoring Extension
7th Sep 202011:06 amRNSSecond Price Monitoring Extn
7th Sep 202011:01 amRNSPrice Monitoring Extension
7th Sep 20209:05 amRNSSecond Price Monitoring Extn
7th Sep 20209:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSCollaboration to co-develop treatment for COVID-19
11th Aug 20207:00 amRNSPositive interim safety review of XF-73 phase 2b
27th Jul 20207:00 amRNSUpdate on Phase 2b clinical study of XF-73
15th Jul 20207:00 amRNSDestiny Pharma notes launch of AMR Action Fund
19th Jun 202011:00 amRNSCancellation and Grant of Options
10th Jun 202012:30 pmRNSResult of AGM
9th Jun 20207:00 amRNSGrant awarded for Cardiff University collaboration
12th May 20203:15 pmRNSPosting of Annual Report and Notice of AGM
4th May 20207:00 amRNSIndependent review supports the potential of XF-73
29th Apr 20207:00 amRNSFinal Results
24th Apr 20207:00 amRNSNotice of Results
3rd Mar 20207:00 amRNSClinical and Business Update
20th Jan 20207:00 amRNSUpdate on the development of XF drug formulations
17th Dec 20197:00 amRNSAPSIC guidelines recommend decolonising S. aureus
2nd Dec 20197:00 amRNSDirectorate Change
2nd Dec 20197:00 amRNSDestiny to present at UK-China AMR Workshop
15th Nov 20197:30 amRNSPresentation at the Investival Showcase
6th Nov 20197:00 amRNSDestiny Pharma to present at World AMR Congress
16th Oct 20197:00 amRNSPositive phase 1 results published in journal
23rd Sep 20197:00 amRNSDirectorate Change
23rd Sep 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
12th Sep 20197:00 amRNSNotice of Results
10th Sep 20197:00 amRNSUniversity of Sheffield Research Collaboration
2nd Sep 20197:00 amRNSXF Drug platform data presented at EuroBiofilms
15th Aug 201912:20 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSPresentation at Gordon Research Conference
19th Jul 20193:12 pmRNSHolding(s) in Company
4th Jun 20192:39 pmRNSGrant of Options
4th Jun 201912:06 pmRNSResult of AGM
12345

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.